Abstract:Abstract Background Hepatocellular carcinoma (HCC) is one of the leading cause of cancer-related death worldwide. SETD2, as the only known methyltransferase for catalyzing trimethylation of histone H3 lysine 36 (H3K36), has been reported to be associated with several cancers. However, the function of SETD2 in HCC is ambiguous. This work aims to research the function and mechanism of SETD2 in HCC based on bioinformation analysis and cell experiments. Methods SETD2 expression and its relationship with prognosis in LIHC patients were evaluated based on the Cancer Genome Atlas (TCGA) database, the effect of SETD2 silencing and overexpression on HCC cell lines was explored according to CCK-8 assay, colony formation assay and wound healing assay. RNA-seq analysis, western blot and chromatin immunoprecipitation (ChIP) assay were used to explore the potential mechanism of SETD2 in HCC. Results The results indicated that SETD2 expression was upregulated and high SETD2 expression was related to poor prognosis in HCC. SETD2 silencing inhibited the proliferation and migration, and SETD2 overexpression promoted the proliferation and migration in HCC cells. RNA-seq data revealed that differentially expressed genes were dramatically enriched in fibroblast growth factor receptor signaling pathway. FGFBP1, as a FGF-binding protein, ranked in the top 10 among the DEGs. The expression of FGFBP1 in SETD2 silencing BEL-7402 cells was significantly decreased. As the downstream effector of FGFR, ERK phosphorylation level had positive correlation with SETD2. Besides, H3K36me3 directly bound to the promoter of FGFBP1 confirmed by ChIP-qPCR. Conclusions Our findings highlight the promotion role of SETD2/H3K36me3 in HCC proliferation and migration via FGFR-ERK signal pathway. Our studies will advance our understanding of epigenetic dysregulation at HCC progression and provide a rationale for SETD2 as potential diagnostic biomarker and therapeutic target in HCC.

Deficiency of Histone H3K36 Methyltransferase SETD2 Inhibits Proliferation and Migration of Hepatocellular Carcinoma Through ERK Pathway

Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.

SETD3 is Regulated by a Couple of Micrornas and Plays Opposing Roles in Proliferation and Metastasis of Hepatocellular Carcinoma.

SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis

The function of histone methyltransferase SETDB1 and its roles in liver cancer

Cell Cycle-Dependent Degradation of the Methyltransferase SETD3 Attenuates Cell Proliferation and Liver Tumorigenesis

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

SETD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells

Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

Histone Methyltransferase SETDB1 Regulates Liver Cancer Cell Growth Through Methylation of P53

SETD2 EXPRESSION AND PROGNOSTIC VALUE IN HEPATOCELLULAR CARCINOMA

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers

Stabilization of SETD3 by deubiquitinase USP27 enhances cell proliferation and hepatocellular carcinoma progression

Histone Methyltransferase SETD2 Inhibits Tumor Growth Via Suppressing CXCL1-mediated Activation of Cell Cycle in Lung Adenocarcinoma

Methyltransferase SETD2 Inhibits Tumor Growth and Metastasis via STAT1‐IL‐8 signaling mediated EMT in lung adenocarcinoma

Prognostic Impact of SET Domain-Containing Protein 8 and Protein Arginine Methyltransferase 5 in Patients with Hepatocellular Carcinoma Following Curative Resection

SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways

EDG2 Enhanced the Progression of Hepatocellular Carcinoma by LPA/PI3K/AKT/ Mtor Signaling.

Reduced Expression of DACT2 Promotes Hepatocellular Carcinoma Progression: Involvement of Methylation-Mediated Gene Silencing

Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation Through the STAT1-CCND1/CDK6 Axis.

Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis